Vikramraj K. Jain

Vikramraj K. Jain

Auto-generated profile, based on publicly available information

Vikramraj K. Jain

Bhagwan Mahaveer Jain Hospital, Bengaluru, Karnataka, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AJAnkit Jain
Ankit Jain
BSBheemanathi Hanuman Srinivas
Bheemanathi Hanuman Srinivas
DEDantis Emmanuel
Dantis Emmanuel
VJVikramraj K. Jain
Vikramraj K. Jain
SPSreejith Parameshwaran
Sreejith Parameshwaran
VNVir Singh Negi
Vir Singh Negi


4 September 2024 in Indian Journal of Rheumatology
Verified
Journal Article
Open access
VJVikramraj Jain
Vikramraj Jain
KMKavitha Mohanasundaram
Kavitha Mohanasundaram
SKSharath Kumar
Sharath Kumar
CKChengappa Kavadichanda
Chengappa Kavadichanda
RVRajendra Varaprasad
Rajendra Varaprasad
BDBg Dharmanand
Bg Dharmanand
Introduction: Due to notable distinctions in infection patterns, vaccine accessibility, and approaches to treatment among patients with autoimmune inflammatory rheumatic diseases (AIRD) in India compared to other regions globally, the Indian Rheumatology Association Vaccine (IRAVAC) group was formed to develop expert panel consensus statements on vaccination for adults with AIRDs in India. Methods: The IRAVAC group comprised seven rheumatologists, one epidemiologist, two infectious disease specialists, one clinical virologist, one specialist nurse, and a patient representative. The group determined the scope of the consensus statements, framed the research questions, and assigned a team of few members to review the evidence who designed the search strategy and conducted the systematic literature search and data extraction. Another group of members subsequently reviewed the articles for each vaccine, prepared a summary, generated draft statements, and assigned them an appropriate level of evidence. Eighty-eight such draft statements were circulated to the members of IRAVAC for review and deliberation. The draft statements were revised accordingly, and the final set of 48 statements on vaccinations for eight diseases was voted upon by the IRAVAC group, with a predefined 75% agreement set as a threshold for acceptance. It is envisaged that these consensus statements related to vaccination in AIRD would be helpful not only to rheumatologists in India but also to those in other countries.

12 December 2015 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
VJVikramraj K. Jain
Vikramraj K. Jain
VNVir Singh Negi
Vir Singh Negi

17 January 2017 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
VNVir Singh Negi
Vir Singh Negi
PDPanneer Devaraju
Panneer Devaraju
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
VJVikramraj K Jain
Vikramraj K Jain
JUJignesh Babulal Usdadiya
Jignesh Babulal Usdadiya
RGReena Gulati
Reena Gulati

1 March 2017 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
KCK. G. Chengappa
K. G. Chengappa
VJVikramraj K. Jain
Vikramraj K. Jain
VNVir Singh Negi
Vir Singh Negi